Evaluation of the cardiac safety of second-generation antihistamines.
Taglialatela
M
M
Department of Neuroscience, School of Medicine, University of Naples, Italy. mtaglial@unina.it
Annunziato
L
L
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D027682:Cation Transport Proteins; D002460:Cell Line; D004268:DNA-Binding Proteins; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D006321:Heart / Q000187:drug effects*; D006634:Histamine H1 Antagonists / Q000009:adverse effects*; D006801:Humans; D009490:Neurosecretory Systems / Q000166:cytology / Q000187:drug effects; D015221:Potassium Channels / Q000378:metabolism; D024642:Potassium Channels, Voltage-Gated; D013564:Sympathetic Nervous System / Q000187:drug effects; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG
D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; C072312:ERG protein, human; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D006634:Histamine H1 Antagonists; C092509:KCNH6 protein, human; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG